Immunology & Autoimmune Deal Benchmarks
Deal terms for rheumatoid arthritis, lupus, IBD, psoriasis, and other autoimmune conditions. Benchmarks derived from 107 verified transactions.
107
Total Deals
$1.6B
Avg Upfront
5
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
52
license
33
acquisition
17
collaboration
1
option
0
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Apellis Pharmaceuticals → Biogen Syfovre + Empaveli (full company acquisition) | acquisition | $5.6B | $6.0B | Mar 2026 |
Kali Therapeutics → Sanofi KT501 | license | $180M | $1.2B | Mar 2026 |
Galapagos → Novartis MOR106 | license | $111M | $1.1B | Mar 2026 |
Theravance → Johnson & Johnson TD-1473 | collaboration | $100M | $1.0B | Mar 2026 |
MorphoSys → Novartis MOR106 | license | $111M | $1.1B | Mar 2026 |
Sino Biopharmaceutical → Sanofi rovadicitinib | license | $135M | $1.5B | Mar 2026 |
Frontier Biotechnologies Inc. → GSK plc | license | $40M | $1.0B | Feb 2026 |
Repertoire Immune Medicines → Eli Lilly and Company DECODE platform | collaboration | $85M | $1.9B | Jan 2026 |
Blueprint Medicines → Sanofi systemic mastocytosis | acquisition | $9.5B | $9.5B | Jul 2025 |
Cabaletta Bio → BMS myastheniaGravis | license | $175M | $1.5B | Jul 2025 |
Benchmark Your Immunology & Autoimmune Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 107 verified immunology & autoimmune transactions.
Run Immunology & Autoimmune Benchmark